Effectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer's Dementia: A 48-Week Real-World Observational Study.
Chiung-Chih ChangLung ChanHsi-Hsien ChouYu-Wan YangTa-Fu ChenTing-Bin ChenChin-I ChenAudrey YangChaur-Jong HuPublished in: Advances in therapy (2021)
The use of the 10 cm2 rivastigmine patch in the mild stage of AD maintained cognitive function at Week 24 and neuropsychiatric function at Week 48. The treatment persistency and safety profile support the clinical tolerability of the rivastigmine patch in the management of mild-to-moderate AD in Taiwan.